(Q36300182)

13 August 2017

1 reference

title

Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome (English)

1 reference

13 August 2017

1 reference

cardiovascular disease

1 reference

1 reference

Sander J Robins

1

1 reference

PubMed ID

16256016

13 August 2017

language of work or name

1 reference

1 November 2005

1 reference

Current cardiology reports

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

6

1 reference

13 August 2017

457-464

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-005-0064-9

13 August 2017

0 references

cites work

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

https://api.crossref.org/works/10.1007%2FS11886-005-0064-9

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-005-0064-9

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-005-0064-9

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-005-0064-9

Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia

21 January 2018

1 reference

12 December 2020

Effects of fenofibrate on lipid parameters in obese rhesus monkeys

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes

1 reference

12 December 2020

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

12 December 2020

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

12 December 2020

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

1 reference

12 December 2020

Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations.

1 reference

12 December 2020

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

12 December 2020

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

1 reference

12 December 2020

Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women

1 reference

12 December 2020

Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System

1 reference

12 December 2020

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

12 December 2020

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

12 December 2020

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

1 reference

12 December 2020

Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for Atherosclerosis

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

1 reference

12 December 2020

Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study

1 reference

12 December 2020

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes

1 reference

12 December 2020

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

1 reference

12 December 2020

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

12 December 2020

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

1 reference

12 December 2020

Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.

1 reference

12 December 2020

Bezafibrate Improves Hypertension and Insulin Sensitivity in Humans

1 reference

12 December 2020

Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

12 December 2020

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients

1 reference

12 December 2020

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

12 December 2020

Mechanisms of fatty acid-induced inhibition of glucose uptake

1 reference

12 December 2020

10.1007/S11886-005-0064-9

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16256016